BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 34269308)

  • 1. Intermediate stage hepatocellular carcinoma: Comparison of the value of inflammation-based scores in predicting progression-free survival of patients receiving transarterial chemoembolization.
    Liu Y; Shi M; Chen S; Wan W; Shen L; Shen B; Qi H; Cao F; Wu Y; Huang T; Chen G; Mo J; Ye D; Zhang Y; Feng Z; Fan W
    J Cancer Res Ther; 2021 Jul; 17(3):740-748. PubMed ID: 34269308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.
    He CB; Lin XJ
    PLoS One; 2017; 12(3):e0174769. PubMed ID: 28355305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation scores predict survival for hepatitis B virus-related hepatocellular carcinoma patients after transarterial chemoembolization.
    Zhou DS; Xu L; Luo YL; He FY; Huang JT; Zhang YJ; Chen MS
    World J Gastroenterol; 2015 May; 21(18):5582-90. PubMed ID: 25987783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
    Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
    Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
    Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
    World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE.
    Schobert IT; Savic LJ; Chapiro J; Bousabarah K; Chen E; Laage-Gaupp F; Tefera J; Nezami N; Lin M; Pollak J; Schlachter T
    Eur Radiol; 2020 Oct; 30(10):5663-5673. PubMed ID: 32424595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging Predictors of Survival in Patients with Single Small Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
    Park C; Kim JH; Kim PH; Kim SY; Gwon DI; Chu HH; Park M; Hur J; Kim JY; Kim DJ
    Korean J Radiol; 2021 Feb; 22(2):213-224. PubMed ID: 32901464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computed tomography radiomic features and clinical factors predicting the response to first transarterial chemoembolization in intermediate-stage hepatocellular carcinoma.
    Shi ZX; Li CF; Zhao LF; Sun ZQ; Cui LM; Xin YJ; Wang DQ; Kang TR; Jiang HJ
    Hepatobiliary Pancreat Dis Int; 2024 Aug; 23(4):361-369. PubMed ID: 37429785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lymphocyte-C-reactive protein ratio as the optimal inflammation-based score in patients with hepatocellular carcinoma underwent TACE.
    Lu LH; Wei W; Li SH; Zhang YF; Guo RP
    Aging (Albany NY); 2021 Feb; 13(4):5358-5368. PubMed ID: 33589570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
    Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
    World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer of the Liver Italian Program score helps identify potential candidates for transarterial chemoembolization in patients with Barcelona Clinic Liver Cancer stage C.
    Li L; Gou CY; Li JY; Achakzai R; Li XH
    Hepatobiliary Pancreat Dis Int; 2016 Apr; 15(2):152-7. PubMed ID: 27020631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inflammation-based prognostic index predicts survival advantage after transarterial chemoembolization in hepatocellular carcinoma.
    Pinato DJ; Sharma R
    Transl Res; 2012 Aug; 160(2):146-52. PubMed ID: 22677364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
    Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
    Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization combined with recombinant human adenovirus type 5 H101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: a prognostic nomogram study.
    He CB; Lao XM; Lin XJ
    Chin J Cancer; 2017 Jul; 36(1):59. PubMed ID: 28728568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
    Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
    Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic changes of the inflammation-based index predict mortality following chemoembolisation for hepatocellular carcinoma: a prospective study.
    Pinato DJ; Karamanakos G; Arizumi T; Adjogatse D; Kim YW; Stebbing J; Kudo M; Jang JW; Sharma R
    Aliment Pharmacol Ther; 2014 Dec; 40(11-12):1270-81. PubMed ID: 25327965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
    Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
    BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel combined systemic inflammation-based score can predict survival of intermediate-to-advanced hepatocellular carcinoma patients undergoing transarterial chemoembolization.
    Liu C; Li L; Lu WS; Du H; Yan LN; Wen TF; Wei WR; Jiang L; Xu MQ
    BMC Cancer; 2018 Feb; 18(1):216. PubMed ID: 29466970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of preoperative aspartate aminotransferase to neutrophil ratio index in patients with hepatocellular carcinoma after hepatic resection.
    Ji F; Fu S; Guo Z; Pang H; Chen D; Wang X; Ju W; Wang D; He X; Hua Y; Peng B
    Oncotarget; 2016 Nov; 7(44):72276-72289. PubMed ID: 27472390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the prognostic value of inflammation-based scores in early recurrent hepatocellular carcinoma after hepatectomy.
    Wang C; He W; Yuan Y; Zhang Y; Li K; Zou R; Liao Y; Liu W; Yang Z; Zuo D; Qiu J; Zheng Y; Li B; Yuan Y
    Liver Int; 2020 Jan; 40(1):229-239. PubMed ID: 31652394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.